Relation Therapeutics secured an expanded research collaboration with GSK worth up to $110 million to generate large-scale cellular perturbation datasets for cellular foundation models. Under the pact, Relation will use automated laboratories to generate petascale, time-resolved, multi-omic readouts intended to improve target discovery confidence. Relation simultaneously unveiled MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), positioning it as a general-purpose cellular model that can predict how cells respond to genetic and pharmacological interventions across disease contexts. The collaboration did not name initial disease areas. For biopharma, the deal signals a push toward model training on standardized, high-consistency perturbation data intended to reduce variability issues that have hampered translational confidence.